Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Cl.Pt |
| Molecular Weight | 265.99 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Pt++]
InChI
InChIKey=CLSUSRZJUQMOHH-UHFFFAOYSA-L
InChI=1S/2ClH.Pt/h2*1H;/q;;+2/p-2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24435208https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdfftp://ftp.nrg.eu/pub/www/nrg/nrglib/2004/immobilisation_of_iodine.pdfCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24435208https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdfftp://ftp.nrg.eu/pub/www/nrg/nrglib/2004/immobilisation_of_iodine.pdf
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039
There is no available sources on the medical use of platinum iodide. The salt is insoluble.
CNS Activity
Curator's Comment: With the injection of cisplatin into mice 3 h after the LPS treatment, platinum was detected in the CCR during the 7 days after the injection, while platinum was not detected in the CCR of cisplatin-injected mice without LPS pretreatment and of mice simultaneous treated with cisplatin and LPS.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311221 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
|||
| Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
|||
| Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
|||
| Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
896SQ4TDHW
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
Platinum(II) chloride
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
49801
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
233-034-1
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
m8913
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
2770
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
6340
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
DTXSID6064901
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
100000184192
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY | |||
|
10025-65-7
Created by
admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
